News Releases
by Year
2013
Dec. 25, 2013 (PDF/94KB) R&D
Dainippon Sumitomo Pharma submits an application for partial change of the approved indication to "Type 2 Diabetes" for SUREPOST, a rapid-acting insulin secretagogue
Dec. 25, 2013 (PDF/111KB) Corporate
Dainippon Sumitomo Pharma Sets Up the Oncology Clinical Development Unit
Dec. 20, 2013 (PDF/66KB) Products
Dainippon Sumitomo Pharma obtains approval in Japan of a partial change in the approved dosage and administration of MEROPEN, a carbapenem antibiotic preparation, when used for the treatment of bacterial meningitis
Dec. 09, 2013 (PDF/113KB) Products
Sunovion Pharmaceuticals Inc. Presents Phase 3 Pooled Analysis of Once-Daily Aptiom (eslicarbazepine acetate) as Adjunctive Treatment for Partial-Onset Seizures
Dec. 09, 2013 (PDF/97KB) R&D
Sunovion Pharmaceuticals Inc. Presents Positive Results From Two Phase 3 Studies of Once-Daily Aptiom(eslicarbazepine acetate) as Monotherapy Treatment for Partial-Onset Seizures
Dec. 02, 2013 (PDF/94KB) R&D
Healios and Dainippon Sumitomo Pharma form an alliancein regenerative medicine and cell therapy--- Joint development of the world’s first regenerative medicine/cell therapy business based on iPS cell technology ---
Nov. 08, 2013 (PDF/43KB) Corporate
A Basic Agreement Reached for Joint Development of New TB Vaccines
Nov. 08, 2013 (PDF/42KB) Products
Sunovion Pharmaceuticals Inc. Announces FDA Approval of Aptiom (eslicarbazepine acetate) as Once-Daily Adjunctive Treatment of Partial-Onset Seizures
Nov. 01, 2013 (PDF/110KB) Products
Sunovion Announces Publication of Two Pivotal Studies Supporting FDA Approval of Latuda (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression in The American Journal of Psychiatry
Oct. 30, 2013 (PDF/105KB) Finances
Dainippon Sumitomo Pharma Announces Posting of Extraordinary Loss (Impairment Loss)
Oct. 30, 2013 (PDF/231KB) Finances
Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2014
Oct. 30, 2013 (PDF/385KB) Finances
Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2014 [Japanese GAAP] (Unaudited)
Oct. 30, 2013 (PDF/80KB) Finances
Dainippon Sumitomo Pharma Announces Variances between Its Financial Forecasts and the Actual Results for the Half-Year Ended September 30, 2013 and Revisions to Its Financial Forecasts for the Full Fiscal Year
Oct. 28, 2013 (PDF/150KB) R&D
Application for Marketing Approval Submitted in Taiwan for Atypical Antipsychotic Agent Lurasidone
Oct. 09, 2013 (PDF/141KB) Corporate
Dainippon Sumitomo Pharma to Establish an Anti-Cancer Drugs Sales Company in the U.S.
Sep. 27, 2013 (PDF/32KB) R&D
Dainippon Sumitomo Pharma submits an application for an atypical antipsychotic blonanserin (Brand name in Japan: LONASEN) in China
Sep. 18, 2013 (PDF/29KB) R&D
Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Acceptance for Review of the New Drug Submission of eslicarbazepine acetate as a Once-Daily Adjunctive Therapy for PartialonsetSeizures in Adults with Epilepsy
Sep. 17, 2013 (PDF/81KB) R&D
Sunovion Reports Eslicarbazepine Acetate Meets Primary Endpoint in Two Phase 3 Monotherapy Studies for Partial-onset Seizures in Adults with Epilepsy
Aug. 13, 2013 (PDF/65KB) Products
DSP and Takeda Announce Approval of the Marketing Authorization Application for Atypical Antipsychotic Agent Lurasidone in Switzerland
Aug. 09, 2013 (PDF/34KB) Corporate
Dainippon Sumitomo Pharma To Set Up the Regenerative & Cellular Medicine Office
Aug. 06, 2013 (PDF/65KB) R&D
Application Submission for Approval for the Stability-Improved Formulation of Limaprost, an Oral Prostaglandin E1 Analogue in Japan
Jul. 31, 2013 (PDF/226KB) Finances
Supplementary Financial Data for the First Quarter of the Year Ending March 31, 2014
Jul. 31, 2013 (PDF/148KB) Finances
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2014 (Unaudited)
Jul. 01, 2013 (PDF/84KB) Corporate
Dainippon Sumitomo Pharma to Have Two Head Offices
Jun. 29, 2013 (PDF/115KB) Products
Sunovion Pharmaceuticals Inc. Announces FDA Approval of Latuda (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression
Jun. 12, 2013 (PDF/47KB) Products
Dainippon Sumitomo Pharma announces the launch of anti-hypertension drug "AVAPRO Tablets 200mg"
Jun. 04, 2013 (PDF/93KB) Corporate
Dainippon Sumitomo Pharma Completes Construction on New Chemistry Research Building
Jun. 04, 2013 (PDF/110KB) R&D
Dainippon Sumitomo Pharma announces BBI608 Phase 1/2 Clinical Study Data (Dose-Escalation Study) was presented at the 2013 ASCO Annual Meeting
May 16, 2013 (PDF/65KB) R&D
Dainippon Sumitomo Pharma announces BBI608 Clinical Study Data to be presented at the 2013 ASCO Annual Meeting
May 09, 2013 (PDF/41KB) R&D
Dainippon Sumitomo Pharma announces BBI608 Phase 1 Clinical Study Data to be presented at the 2013 ASCO Annual Meeting
May 09, 2013 (PDF/229KB) Finances
Supplementary Financial Data for the Year Ended March 31, 2013
May 09, 2013 (PDF/505KB) Finances
Summary of Consolidated Financial Results for the Year Ended March 31, 2013 [Japanese GAAP] (Unaudited)
May 09, 2013 (PDF/66KB) Corporate
Change of Directors and Audit & Supervisory Board Members
May 08, 2013 (PDF/24KB) Licensing
Ono and Dainippon Sumitomo reach agreement on expanding business relating to Limaprost into China
Apr. 15, 2013 (PDF/34KB) R&D
Dainippon Sumitomo Pharma Submits Marketing Authorization Application in Australia for Atypical Antipsychotic Agent Lurasidone
Apr. 08, 2013 (PDF/23KB) R&D
Dainippon Sumitomo Pharma and Chugai Pharmaceutical Terminate Joint Development of Cancer Vaccine
Apr. 03, 2013 (PDF/42KB) Corporate
Dainippon Sumitomo Pharma announces name change of its European subsidiary to Sunovion Pharmaceuticals Europe
Mar. 29, 2013 (PDF/31KB) Licensing
Dainippon Sumitomo Pharma signs a License Agreement with Edison Pharmaceuticals for therapeutic agents for mitochondria disease
Mar. 28, 2013 (PDF/40KB) Corporate
Retina Institute Japan and Dainippon Sumitomo Pharma form a capital alliance towards the development of Nobel Prize winning iPS cell technology
Mar. 07, 2013 (PDF/22KB) Licensing
Dainippon Sumitomo Pharma and Nippon Shinyaku conclude a license agreement for SMP-986, a therapeutic agent for urology
Mar. 04, 2013 (PDF/64KB) Corporate
Dainippon Sumitomo Pharma announces reorganization of its Research and Development
Feb. 28, 2013 (PDF/48KB) Products
Dainippon Sumitomo Pharma obtains approval for SUREPOST, a rapid-acting insulin secretagogue, for the additional indications of combination therapy with biguanides and with thiazolidinediones
Feb. 28, 2013 (PDF/138KB) R&D
Sunovion Announces FDA Acceptance for Review of New Drug Application Resubmission for STEDESA (eslicarbazepine acetate) as a Once-Daily Adjunctive Therapy for Partial-onset Seizures in Adults with Epilepsy
Feb. 18, 2013 (PDF/59KB) Finances
Dainippon Sumitomo Pharma announces its Third Mid-term Business Plan
Jan. 31, 2013 (PDF/484KB) Finances
Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2013
Jan. 31, 2013 (PDF/221KB) Finances
Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2013 (Unaudited)
Jan. 25, 2013 (PDF/17KB) R&D
Discontinuation of Development for the Additional Indication of Carpal-Tunnel Syndrome, for Limaprost, an Oral Prostaglandin E1 Analogue
Jan. 22, 2013 (PDF/44KB) R&D
Dainippon Sumitomo Pharma files an application in Japan for a partial change in the approved dosage and administration of MEROPEN, a carbapenem antibiotic preparation, when used for the treatment of bacterial meningitis
Jan. 21, 2013 (PDF/62KB) Corporate
Dainippon Sumitomo Pharma establishes a Subsidiary in Singapore